CN105535263A - Medicine composition for treating ascites due to cirrhosis and preparation method thereof - Google Patents
Medicine composition for treating ascites due to cirrhosis and preparation method thereof Download PDFInfo
- Publication number
- CN105535263A CN105535263A CN201610047133.3A CN201610047133A CN105535263A CN 105535263 A CN105535263 A CN 105535263A CN 201610047133 A CN201610047133 A CN 201610047133A CN 105535263 A CN105535263 A CN 105535263A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- pharmaceutical composition
- ethanol
- weight
- percent concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a medicine composition for treating ascites due to cirrhosis and a preparation method thereof. The medicine composition is prepared from northern bedstraw, Staphylea pinnata, Butea monosperma, Adinandra mellettii and Vernonia patula in a matching mode. Various dosage forms can be prepared according to a normal formulation technology, and the medicine composition has the remarkable effect on treating ascites due to cirrhosis.
Description
Technical field
The invention belongs to technical field of Chinese medicines, particularly relate to a kind of pharmaceutical composition for the treatment of cirrhotic ascites and preparation method thereof.
Background technology
The category that cirrhotic ascites belongs to " tympanites ", form the pathogenesis of hepatic ascites first due to function of liver and spleen imbalance, wood Yu Ke soil, cause renal involvement, define liver, spleen, the functional disorder of kidney is " in clinical, the treatment of Western medicine to cirrhotic ascites there is no good effect, general employing venoclysis albumin and beat the methods such as diuresis pin and treat, though the misery of patient temporarily can be explained to a certain extent, but conditions of patients easily repeatedly, and bring larger financial burden to patient, and traditional Chinese medical herbal treatment cirrhotic ascites, not only determined curative effect, and the relapse rate of patient is lower, " its therapy mechanism is according to patient's liver cirrhosis, there is the basic reason of development in hepatic ascites, establish resolving depression regulating QI, soft liver easing the affected liver and a spleen invigorating! the rule of harmonization of the stomach nourishing YIN to promote diuresis, for the course of disease that patient is different! the state of an illness is dialectical to because treating, and the cirrhotic ascites therapeutic effect especially to slight is particularly evident, and patient is many, and the state of an illness is in the short period of time controlled, ascites is disappeared, and " after the treatment difficulty of hepatic ascites is that patient cures, the consolidation difficulty of disease, the state of an illness easily repeatedly, and easily develops into liver failure or primary hepatoma, prognosis is poor " therefore, in the therapeutic process of Chinese medicine, notice that the deficiency and excess of primary disease is held concurrently mutually, Chinese traditional treatment will focus on reinforcement and elimination in combination, tonify deficiency does not forget reality, lets out and does not forget void in fact ".
Adinandra millettii: this product is Theaceae Adinandra millettii platymiscium Adinandra millettii Adinandramillettii(Hook.etArn.) root of Benth.etHook.f. and tender leaf.Root can be adopted the whole year, dries.Tender leaf summer, Qiu Cai, using fresh herb.[nature and flavor] are bitter; Cool.[return through] lung; Liver Channel.[function cures mainly] cooling blood for hemostasis; Removing toxic substances and promoting subsidence of swelling.Main epistaxis; Hematuria; Infectious hepatitis; Parotitis; Furuncle and phyma; Snake bite and insect sting; Cancerous protuberance.[former phytomorph] Adinandra millettii shrub or dungarunga, height is 5m about.Twig and terminal bud dredge raw pubescence.Single leaf alternate; Leaf tool short handle; Blade heavy leather matter, oval shape is oval, long 4.5-9cm, wide 2-3cm, the short point of tip, and base portion is gradually narrow, the full edge in edge, rare at the first half slightly denticulation, and have intensive pubescence during children, rear change is without hair.Flower both sexes, are singly born in axil; Bennet is very thin, is about 2cm, and have and paste volt undercoat, sepal 5, ovum shape triangle, volt undercoat is pasted in outside, and edge is bordering on film quality, has thin gland tooth and eyelashes; Corolla lobe 5, without hair; About 25 pieces, stamen, the white pubescence of the close life of flower pesticide; Ovary is upper, Room 3, and adularescent pubescence, style is without hair.Berry is subsphaeroidal, diameter 7-8mm, has pubescence or is bordering on without hair.Seed is tiny, black, light.Record in Chinese medicine voluminous dictionary.
Northern bedstraw: be the herb of Rubiaceae clivers Herba Galii borealis GaliumborealeL..Autumn gathers, and cutting is dried.[nature and flavor] are bitter; Cold.[function cures mainly] heat-clearing and toxic substances removing; Expelling wind and activating blood circulation.Main pneumonia cough; Oedema due to nephritis; Lumbago and skelalgia; Women's amenorrhea; Dysmenorrhea; Leukorrhagia; Skin ulcer tinea.[chemical analysis] is containing quintessence oil, Coumarins, flavonoid and anthraquinone analog compound.[former phytomorph] Herba Galii borealis, perennial vertical herbage, high 20-50cm.Stem tool four rib, has branch, closely has microtriche without hair or joint portion.4, leaf is verticillate; Stockless; Blade wire lanceolar, long 1-3.5cm, wide 2-4mm, tip is blunt, the wealthy wedge shape of base portion or subcircular, and edge is warp slightly.Base goes out 3, arteries and veins, and except there is microtriche at edge, two without hair.Cyme top is raw, or forms the panicle shape of band leaf at Zhi Ding; Hua Mi, little, yellow-white; The long 3-5mm of pedicel; Sepal 4, ellipticity is avette, has thin hair, the short gradually point of tip; Stamen 4, with sepal alternate; Ovary is the next, and subsphaeroidal, style 2 splits to nearly base portion.Fruit is spherical, little, black, close by white glochild.The florescence 6-8 month, the fruit phase 7-9 month.Record in Chinese medicine voluminous dictionary.
Fructus Staphyleae Bumaldae: this product is Palmae Daemonorops plant Caulis Fibraureae Daemonoropsmargaritae(Hance) Becc. [CalamusmargaritaeHance ］ stem.The whole year all can adopt, and cutting is dried.[nature and flavor] bitter in the mouth; Property is put down.[function cures mainly] anthelmintic; Treating stranguria; Wind dispelling pain relieving.Main ascarid; Pinworm; Taeniasis; Urine leaching pain; Toothache.[former phytomorph] Caulis Fibraureae, the large liana of spinosity.Stem is upright at the beginning, after climb up by holding on to shape.Leaf pinniform is totally cleaved, total length 2-3m, and rachis top extends into the fine whip of tool claw-like thorn; Sliver closely to life, 50-75 couple, strip lanceolar, long 25-45cm, wide l-2cm, tip is gradually sharp, and there is the thorn of the lower curved or rigidness that differs in size at the rachis back side; Sheath is without fine whip but have flat thorn.Spadix encloses for spathe before blooming, and in spindle, long 25-30cm, Zhu Duan shape of tail is gradually sharp, and 1 piece, outside is close by brown, flat straight thrust, and the spathe of the inside stings or stingless less, and after yielding positive results, spathe comes off.Rachilla on staminate inflorescence is intensive, is about 3cm, spends intensive, and the oval shape of male flower is avette, long 5mm; Calyx cup-shaped, shallow 3 teeth; Corolla 3 splits, and is longer than calyx for about 2 times; Stamen 6, is about 3.5mm, involucre tazza shape.Female flower: calyx short cylinder shaped, tip 3 fissure; Petal lanceolar, is about 2 times into calyx; Ovary is avette, 3 pieces, stigma.Fruit is spherical, diameter 1.8-2cm, has the scale of the capable file of 18-20, and scale has 10-20 on every 1 row, yellow and bright, has groove stricture of vagina.The seed kidney shape is spherical.May at florescence, the fruit phase 6-10 month.Record in Chinese medicine voluminous dictionary.
Herba Vernoniae Patulae: be the herb of ironweed plant Herba Vernoniae Patulae Vernoniapatula (Ait.) Merr. [ConyzapatulaDryand.].The whole year all can gather, and cleans, dries.[nature and flavor] bitter in the mouth; Pungent; Property is put down.The heat clearing away of [function cures mainly] fresh breeze; Eliminating damp, detoxifying; Dissipating blood stasis for subsidence of swelling.Main cold, fever; Malaria; Close pain; Hypertension; Have loose bowels; Dysentery; Rheumatic arthralgia; Eczema; Herba Urticae Cannabinae is examined; Furuncle; Mastitis; The tuberculosis of cervical lymph nodes; Traumatic injury.The thick 4-8mm of [character] stem, stem branch, all in taupe brown or yellow green, has obvious vertical stripe and Lycoperdon polymorphum Vitt pubescence, and matter is hard and crisp, and there is marrow at section center.Leaf alternate, how broken, celadon or to yellowish-brown, by Lycoperdon polymorphum Vitt pubescence.Sprig is with infructescence usually, and achene is cylindrical, has 4-5 rib, without hair, has gland point, and pappus white, easily comes off.Feeble QI, mildly bitter flavor.[chemical analysis] root is containing flavonoid glycoside, triterpene, plant sterol, volatile oil, aminoacid, organic acid.Record in Chinese medicine voluminous dictionary.
Purple ore deposit: the dry mature seed of Buteamonosperma (Lam.) Kuntze..Main product is in the ground such as Yunnan, Guangxi.Gather during pod maturation in summer, lay seed, Ex-all impurity, dries.[nature and flavor] are bitter, sweet, temperature.[function with cure mainly] anthelmintic, yellow fluid reducing, relieving itching.For parasitosis, grasserie, skin pruritus.[character] this product is flat kidney shape, avette, class triangle, long 2 ~ 4cm, wide 1.5 ~ 3cm, thick about 2mm, outer surface chocolate, glossy, tool vein and wrinkle, or slightly smooth, sometimes the remaining brown membranaceous endocarp of part, matt, occasionally there is patagium to invest outside seed.Hilum is obvious, and inside it, plumule position is slightly thick, and hilum is often recessed into, be positioned at seed slightly recessed or truncate middle part or slightly biased, the seedstalk of each about 2mm of visible length and width sometimes.Matter heavily fortified point is crisp, frangibility; Section yellowish white, cutin shape, oiliness, seed coat is thin, can peel off by small pieces, outer taupe, and internal layer is fallow; Cotyledon is flat, large-scale, lobate, yellowish white, easily from strip off between two cotyledons.Feeble QI, somewhat beany flavor.Record in Qinghai Province's Tibetan medicine concocted specification (version in 2010).
Summary of the invention
The object of the invention is the deficiency overcoming background technology, pharmaceutical composition of a kind of effective treatment cirrhotic ascites and preparation method thereof is provided.
The present invention adopts following technical scheme to realize:
Composition and the weight portion of making the crude drug of the pharmaceutical composition of this treatment cirrhotic ascites are:
The purple ore deposit of northern bedstraw 3420-3460 weight portion Fructus Staphyleae Bumaldae 2100-2400 weight portion 200-300 weight portion Adinandra millettii 1220-1300 weight portion Herba Vernoniae Patulae 500-660 weight portion.
Preferably be used for the treatment of the pharmaceutical composition of cirrhotic ascites, be made up of the crude drug of following weight portion:
Northern bedstraw 3440 weight portion Fructus Staphyleae Bumaldae 2250 weight portion purple ore deposit son 250 weight portion Adinandra millettii 1260 weight portion Herba Vernoniae Patulae 580 weight portions.
Treat a pharmaceutical composition for cirrhotic ascites, it is characterized in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to be prepared into tablet or capsule or drop pill.
Treat a pharmaceutical composition for cirrhotic ascites, it is characterized in that the treatment cirrhotic ascites medicine that pharmaceutical composition and chemical drugs or Chinese medicine form.
Treat a preparation method for the pharmaceutical composition of cirrhotic ascites, it is characterized in that preparing as follows:
The composition of crude drug and weight portion are: the purple ore deposit of northern bedstraw 3420-3460 weight portion Fructus Staphyleae Bumaldae 2100-2400 weight portion 200-300 weight portion Adinandra millettii 1220-1300 weight portion Herba Vernoniae Patulae 500-660 weight portion;
Preparation method:
(1) northern bedstraw is got by crude drug proportioning, Fructus Staphyleae Bumaldae, purple ore deposit, Adinandra millettii, Herba Vernoniae Patulae, mixing, with weight percent concentration 21% ethanol as solvent, extract at 25 DEG C of warm macerating, extraction time is 21 times, each extraction time is 5.8 hours, each solvent load is 19.5 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, be concentrated into relative density 1.18, filter, medicinal liquid is by HP30 macroporous adsorptive resins, first wash with water, use weight percent concentration 75% alcoholic solution eluting HP30 macroporous adsorptive resins again, collect weight percent concentration 75% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is got, with weight percent concentration 37% ethanol as solvent, heating and refluxing extraction 13 times, each extraction time is 2.2 hours, each solvent load is 16 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, be concentrated into relative density 1.11, filter, medicinal liquid is by D743 macroporous adsorptive resins, first wash with water, use weight percent concentration 77% alcoholic solution eluting D743 macroporous adsorptive resins again, collect weight percent concentration 77% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) by extract A and extract B mixing, pharmaceutical composition is obtained.
Preferably treat a preparation method for the pharmaceutical composition of cirrhotic ascites, it is characterized in that preparing as follows:
The composition of crude drug and weight portion are: northern bedstraw 3440 weight portion Fructus Staphyleae Bumaldae 2250 weight portion purple ore deposit son 250 weight portion Adinandra millettii 1260 weight portion Herba Vernoniae Patulae 580 weight portions;
Preparation method:
(1) northern bedstraw is got by crude drug proportioning, Fructus Staphyleae Bumaldae, purple ore deposit, Adinandra millettii, Herba Vernoniae Patulae, mixing, with weight percent concentration 21% ethanol as solvent, extract at 25 DEG C of warm macerating, extraction time is 21 times, each extraction time is 5.8 hours, each solvent load is 19.5 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, be concentrated into relative density 1.18, filter, medicinal liquid is by HP30 macroporous adsorptive resins, first wash with water, use weight percent concentration 75% alcoholic solution eluting HP30 macroporous adsorptive resins again, collect weight percent concentration 75% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is got, with weight percent concentration 37% ethanol as solvent, heating and refluxing extraction 13 times, each extraction time is 2.2 hours, each solvent load is 16 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, be concentrated into relative density 1.11, filter, medicinal liquid is by D743 macroporous adsorptive resins, first wash with water, use weight percent concentration 77% alcoholic solution eluting D743 macroporous adsorptive resins again, collect weight percent concentration 77% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) by extract A and extract B mixing, pharmaceutical composition is obtained.
Treat a preparation method for the pharmaceutical composition of cirrhotic ascites, it is characterized in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to be prepared into tablet or capsule or drop pill.
Treat a preparation method for the pharmaceutical composition of cirrhotic ascites, it is characterized in that pharmaceutical composition and chemical drugs or Chinese medicine form and treat cirrhotic ascites medicine.
Medicine composite for curing cirrhotic ascites is evident in efficacy.
Detailed description of the invention
Embodiment 1: pharmaceutical composition for the treatment of cirrhotic ascites and preparation method thereof
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of cirrhotic ascites are: the purple ore deposit sub-250g Adinandra millettii 1260g Herba Vernoniae Patulae 580g of northern bedstraw 3440g Fructus Staphyleae Bumaldae 2250g;
Preparation method:
(1) northern bedstraw is got by crude drug proportioning, Fructus Staphyleae Bumaldae, purple ore deposit, Adinandra millettii, Herba Vernoniae Patulae, mixing, with weight percent concentration 21% ethanol as solvent, extract at 25 DEG C of warm macerating, extraction time is 21 times, each extraction time is 5.8 hours, each solvent load is 19.5 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, be concentrated into relative density 1.18, filter, medicinal liquid is by HP30 macroporous adsorptive resins, first wash with water, use weight percent concentration 75% alcoholic solution eluting HP30 macroporous adsorptive resins again, collect weight percent concentration 75% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is got, with weight percent concentration 37% ethanol as solvent, heating and refluxing extraction 13 times, each extraction time is 2.2 hours, each solvent load is 16 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, be concentrated into relative density 1.11, filter, medicinal liquid is by D743 macroporous adsorptive resins, first wash with water, use weight percent concentration 77% alcoholic solution eluting D743 macroporous adsorptive resins again, collect weight percent concentration 77% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) by extract A and extract B mixing, pharmaceutical composition is obtained.
Embodiment 2: pharmaceutical composition for the treatment of cirrhotic ascites and preparation method thereof
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of cirrhotic ascites are: the purple ore deposit sub-200g Adinandra millettii 1300g Herba Vernoniae Patulae 500g of northern bedstraw 3420g Fructus Staphyleae Bumaldae 2400g;
Preparation method:
(1) northern bedstraw is got by crude drug proportioning, Fructus Staphyleae Bumaldae, purple ore deposit, Adinandra millettii, Herba Vernoniae Patulae, mixing, with weight percent concentration 21% ethanol as solvent, extract at 25 DEG C of warm macerating, extraction time is 21 times, each extraction time is 5.8 hours, each solvent load is 19.5 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, be concentrated into relative density 1.18, filter, medicinal liquid is by HP30 macroporous adsorptive resins, first wash with water, use weight percent concentration 75% alcoholic solution eluting HP30 macroporous adsorptive resins again, collect weight percent concentration 75% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is got, with weight percent concentration 37% ethanol as solvent, heating and refluxing extraction 13 times, each extraction time is 2.2 hours, each solvent load is 16 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, be concentrated into relative density 1.11, filter, medicinal liquid is by D743 macroporous adsorptive resins, first wash with water, use weight percent concentration 77% alcoholic solution eluting D743 macroporous adsorptive resins again, collect weight percent concentration 77% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) by extract A and extract B mixing, pharmaceutical composition is obtained.
Embodiment 3: pharmaceutical composition for the treatment of cirrhotic ascites and preparation method thereof
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of cirrhotic ascites are: the purple ore deposit sub-300g Adinandra millettii 1220g Herba Vernoniae Patulae 660g of northern bedstraw 3460g Fructus Staphyleae Bumaldae 2100g;
Preparation method:
(1) northern bedstraw is got by crude drug proportioning, Fructus Staphyleae Bumaldae, purple ore deposit, Adinandra millettii, Herba Vernoniae Patulae, mixing, with weight percent concentration 21% ethanol as solvent, extract at 25 DEG C of warm macerating, extraction time is 21 times, each extraction time is 5.8 hours, each solvent load is 19.5 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, be concentrated into relative density 1.18, filter, medicinal liquid is by HP30 macroporous adsorptive resins, first wash with water, use weight percent concentration 75% alcoholic solution eluting HP30 macroporous adsorptive resins again, collect weight percent concentration 75% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is got, with weight percent concentration 37% ethanol as solvent, heating and refluxing extraction 13 times, each extraction time is 2.2 hours, each solvent load is 16 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, be concentrated into relative density 1.11, filter, medicinal liquid is by D743 macroporous adsorptive resins, first wash with water, use weight percent concentration 77% alcoholic solution eluting D743 macroporous adsorptive resins again, collect weight percent concentration 77% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) by extract A and extract B mixing, pharmaceutical composition is obtained.
Embodiment 4: the preparation of tablet
Example 1 pharmaceutical composition 361.5g, adds starch 279g, mixing, granulates, dry, adds microcrystalline Cellulose 126.5g, magnesium stearate 4.7g, and mixing, is pressed into 1500, obtains medicinal composition tablets.
Embodiment 5: the preparation of capsule
Example 2 pharmaceutical composition 376.5g, adds starch 245.5g, mixing, granulates, and dry, granulate, adds appropriate magnesium stearate, and mixing, obtains medicament composition capsule by encapsulated 1500.
Embodiment 6: the preparation of drop pill
Taking polyethylene glycol 6000 222.5g water-bath (80 DEG C) heating boils molten, add embodiment 3 pharmaceutical composition 20.7g, stirring, is coolant with liquid paraffin, puts in glass tubing (4*80cm), chilling temperature is 7 DEG C, drip internal-and external diameter is 7.0/2.0 (mm/mm), and drip is 2.5cm apart from liquid level, drips speed with per minute 70 for optimum condition, blot the condensing agent on drop pill surface with cotton, obtain medicament composition dropping pills.
Embodiment 7: the pharmaceutical composition for the treatment of cirrhotic ascites
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of cirrhotic ascites are:
Purple ore deposit son 450 weight portion Adinandra millettii 1160 weight portion Fructus Staphyleae Bumaldae 1250 weight portions.
Embodiment 8: the pharmaceutical composition for the treatment of cirrhotic ascites
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of cirrhotic ascites are:
Purple ore deposit son 320 weight portion Adinandra millettii 1370 weight portion Herba Vernoniae Patulae 890 weight portions.
Embodiment 9: the pharmaceutical composition for the treatment of cirrhotic ascites
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of cirrhotic ascites are:
Purple ore deposit son 70 weight portion Adinandra millettii 1140 weight portion Herba Vernoniae Patulae 536 weight portions.
Experimental example 1: the experimental study for the treatment of cirrhotic ascites
1 clinical data
All 42 examples (containing matched group 21 example) patient is inpatient.The diagnosis all meeting posthepatitic cirrhosis, liver function Decompensated stage is checked through liver function, hepatitis series.All cases are divided into two groups at random.Treatment group: pharmaceutical composition is major-minor with western medicine routine treatment totally 21 examples.Wherein male 10 example, women 11 example.Age 22-65 year, 41.6 ± 10.25 years old mean age.The course of disease is the longest 12 years, the shortest 8 months, average course of disease 56.5 ± 31.33 months.Matched group: take western medicine as main totally 21 examples.Wherein male 11 example, women 10 example.Age 21-64 year, 42.2 ± 9.8 years old mean age.The course of disease is the longest 11 years, the shortest 8 months, average course of disease 55.4 ± 30.8 months.Two groups are compared the age, the course of disease, state of an illness weight have comparability, there was no significant difference (P>0.05).
2 Therapeutic Method
2.1 treatment group
Combination of oral medication (embodiment 1 pharmaceutical composition lot number 20110624), each 1g, every day 3 times, applies diuresis if desired, protects the liver, mends the methods such as albumen.
2.2 matched group
Conventional application spironolactone 40mg/d, SHUANGKE 25mg, 2 times/d, treatment starts to share 3d-6d with spironolactone, and row abdomen is worn if desired, puts ascites, and to albumin 1g/ time, 1-2 time, cooperation liver is pacified, potenlin protects the liver.
Patient is at while in hospital medication 25d-40d.Liver function, Abdominal B type ultrasonography is respectively chemically examined 1 time during people institute and before leaving hospital.The 30d-60d that takes medicine is continued after leaving hospital.Follow up a case by regular visits to after 6 months and chemically examine liver function, Abdominal B type ultrasonography 1 time.
2.3 criterion of therapeutical effect
2.3.1 liver function and ascites scoring
Liver function is by Cihld staging: be designated as 0 point below A level; A level is 2 points; B level is 4 points; C level is 6 points.Ascites, with reference to interrelated data, is divided into 3 degree: I degree in conjunction with B ultrasonic and clinical health check-up: a small amount of, ascites volume <1000ml, dull percussion note during knee-elbow position.Umbilical part tympanitic resonance during dorsal position.Shifting dullness is not obvious.II degree: middle amount, ascites volume 1100-3000ml, shifting dullness is obvious.But abdominal part voiced sound circle is no more than inside the ilium center line extended line of both sides during dorsal position.
degree: a large amount of,>=3000ml, both sides are raised abdomen wall tension simultaneously and are disappeared, and concavo-convex of umbilicus, can not put down sleeping.0 point is designated as without ascites; I degree is designated as 2 points; II degree is designated as 4 points;
degree is designated as 6 points.
2.3.2 symptom score
Score by following Syndrome Scale: abdominal distention, poor appetite, weak, loose stool, oliguria., accidentally there is note 1 point in asymptomatic note 0 point, often occurs having no significant effect note 2 points to life, and often appearance or sustainable existence have a strong impact on life note 3 points.
2.3.3 efficacy determination
Clinical symptoms disappears completely, integration improvement rate >=90%, is clinic control.Symptom, sign obviously alleviate, and integration improvement rate is effective more than 70%.Symptom, sign take a turn for the better, and integration improvement rate is improvement more than 35%.Symptom, sign are without alleviating or increasing the weight of, and integration improvement rate is invalid below 35%.
3 therapeutic outcomes
3.1 comprehensive therapeutic effect analyses
The results are shown in Table 1.
A table 1 liang group comprehensive therapeutic effect compares
Show in table, treatment group total effective rate 95.24%, matched group total effective rate is 76.19%, shows that the short term effect for the treatment of group is obviously better than matched group, P<0.05.
Follow-up care group 16 example after half a year, matched group 13 example, general curative effect is in table 2.
Two groups of comparitive study followed up a case by regular visits to by table 2
Wherein treatment group total effective rate 93.75%, the late result of matched group total effective rate 76.92%, two groups of comparative descriptions treatment groups is obviously better than matched group, P<0.05.
3.2 case citings
Patient Zhang, female, 39 years old, peasant.December in 2011 is in hospital on the 27th, main suit: " weak, poor appetite more than 2 years.Increasing the weight of and abdominal distention February " patient often feels weak without obvious cause over nearly 2 years, poor appetite, spirit are poor, detest oil, idol has nauseating, right hypochondrial region.Do not control.Nearly February exacerbation of symptoms, weak poor appetite, becomes thin, abdominal distention, oliguria, large loose stool, and mind is clear, and spirit is poor, and complexion is burned black, white of the eye xanthochromia.Cardiopulmonary are without exception, abdominal part Peng Long, and shifting dullness is positive: edema that lower limb are slight.Light red tongue, white and thin fur, stringy and thready pulse.Liver function is chemically examined: ALT102U/L, AST121U/L after being admitted to hospital.Total bilirubin 35mmol/L, total protein 64G/L, albumin 26G/L, globulin 39G/L, Archon ratio 0.65.B ultrasonic: ascites is about 2500ml.Hepatitis series: HBsAg (+), HBeAg (+), Ant-HBeAg (+).AD: 1. chronic active hepatitis B.2. posthepatitic cirrhosis.Liver function B level.Be main treatment (oral embodiment 1 pharmaceutical composition, each 1g, every day 3 times) with pharmaceutical composition after being admitted to hospital.While in hospital takes medicine 20 days, coordinates oral spironolactone 40mg/d, defeated albumin 10g.Check liver function ALT43U/L, AST32U/L, albumin 32G/L, globulin 32G/L.To leave hospital the follow-up compositions 60 days of taking medicine.Subjective symptoms disappears, and spirit food is received normal.Check liver function ALT32U/L, AST40U/L, albumin 33G/L, globulin 31G/L.Clinical cure, stable disease.
Claims (8)
1. treat a pharmaceutical composition for cirrhotic ascites, it is characterized in that the composition of the crude drug making this pharmaceutical composition and weight portion are:
The purple ore deposit of northern bedstraw 3420-3460 weight portion Fructus Staphyleae Bumaldae 2100-2400 weight portion 200-300 weight portion Adinandra millettii 1220-1300 weight portion Herba Vernoniae Patulae 500-660 weight portion.
2. a kind of pharmaceutical composition for the treatment of cirrhotic ascites according to claim 1, is characterized in that the composition of the crude drug making this pharmaceutical composition and weight portion are:
Northern bedstraw 3440 weight portion Fructus Staphyleae Bumaldae 2250 weight portion purple ore deposit son 250 weight portion Adinandra millettii 1260 weight portion Herba Vernoniae Patulae 580 weight portions.
3. a kind of pharmaceutical composition for the treatment of cirrhotic ascites according to claim 1, is characterized in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to be prepared into tablet or capsule or drop pill.
4. a kind of pharmaceutical composition for the treatment of cirrhotic ascites according to claim 1, is characterized in that the treatment cirrhotic ascites medicine that pharmaceutical composition and chemical drugs or Chinese medicine form.
5. treat a preparation method for the pharmaceutical composition of cirrhotic ascites, it is characterized in that preparing as follows:
The composition of crude drug and weight portion are: the purple ore deposit of northern bedstraw 3420-3460 weight portion Fructus Staphyleae Bumaldae 2100-2400 weight portion 200-300 weight portion Adinandra millettii 1220-1300 weight portion Herba Vernoniae Patulae 500-660 weight portion;
Preparation method:
(1) northern bedstraw is got by crude drug proportioning, Fructus Staphyleae Bumaldae, purple ore deposit, Adinandra millettii, Herba Vernoniae Patulae, mixing, with weight percent concentration 21% ethanol as solvent, extract at 25 DEG C of warm macerating, extraction time is 21 times, each extraction time is 5.8 hours, each solvent load is 19.5 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, be concentrated into relative density 1.18, filter, medicinal liquid is by HP30 macroporous adsorptive resins, first wash with water, use weight percent concentration 75% alcoholic solution eluting HP30 macroporous adsorptive resins again, collect weight percent concentration 75% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is got, with weight percent concentration 37% ethanol as solvent, heating and refluxing extraction 13 times, each extraction time is 2.2 hours, each solvent load is 16 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, be concentrated into relative density 1.11, filter, medicinal liquid is by D743 macroporous adsorptive resins, first wash with water, use weight percent concentration 77% alcoholic solution eluting D743 macroporous adsorptive resins again, collect weight percent concentration 77% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) by extract A and extract B mixing, pharmaceutical composition is obtained.
6. a kind of preparation method for the treatment of the pharmaceutical composition of cirrhotic ascites according to claim 5, is characterized in that preparing as follows:
The composition of crude drug and weight portion are: northern bedstraw 3440 weight portion Fructus Staphyleae Bumaldae 2250 weight portion purple ore deposit son 250 weight portion Adinandra millettii 1260 weight portion Herba Vernoniae Patulae 580 weight portions;
Preparation method:
(1) northern bedstraw is got by crude drug proportioning, Fructus Staphyleae Bumaldae, purple ore deposit, Adinandra millettii, Herba Vernoniae Patulae, mixing, with weight percent concentration 21% ethanol as solvent, extract at 25 DEG C of warm macerating, extraction time is 21 times, each extraction time is 5.8 hours, each solvent load is 19.5 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, be concentrated into relative density 1.18, filter, medicinal liquid is by HP30 macroporous adsorptive resins, first wash with water, use weight percent concentration 75% alcoholic solution eluting HP30 macroporous adsorptive resins again, collect weight percent concentration 75% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is got, with weight percent concentration 37% ethanol as solvent, heating and refluxing extraction 13 times, each extraction time is 2.2 hours, each solvent load is 16 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, be concentrated into relative density 1.11, filter, medicinal liquid is by D743 macroporous adsorptive resins, first wash with water, use weight percent concentration 77% alcoholic solution eluting D743 macroporous adsorptive resins again, collect weight percent concentration 77% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) by extract A and extract B mixing, pharmaceutical composition is obtained.
7. a kind of preparation method for the treatment of the pharmaceutical composition of cirrhotic ascites according to claim 5, is characterized in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to be prepared into tablet or capsule or drop pill.
8. a kind of preparation method for the treatment of the pharmaceutical composition of cirrhotic ascites according to claim 5, is characterized in that pharmaceutical composition and chemical drugs or Chinese medicine form and treats cirrhotic ascites medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610047133.3A CN105535263A (en) | 2016-01-25 | 2016-01-25 | Medicine composition for treating ascites due to cirrhosis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610047133.3A CN105535263A (en) | 2016-01-25 | 2016-01-25 | Medicine composition for treating ascites due to cirrhosis and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105535263A true CN105535263A (en) | 2016-05-04 |
Family
ID=55815174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610047133.3A Withdrawn CN105535263A (en) | 2016-01-25 | 2016-01-25 | Medicine composition for treating ascites due to cirrhosis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105535263A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106727958A (en) * | 2016-12-10 | 2017-05-31 | 济南昊雨青田医药技术有限公司 | It is a kind of to treat pharmaceutical composition of alcoholic hepatitis and preparation method thereof |
| CN106822588A (en) * | 2016-12-10 | 2017-06-13 | 济南昊雨青田医药技术有限公司 | Treat pharmaceutical composition of alcoholic hepatitis and preparation method thereof |
-
2016
- 2016-01-25 CN CN201610047133.3A patent/CN105535263A/en not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106727958A (en) * | 2016-12-10 | 2017-05-31 | 济南昊雨青田医药技术有限公司 | It is a kind of to treat pharmaceutical composition of alcoholic hepatitis and preparation method thereof |
| CN106822588A (en) * | 2016-12-10 | 2017-06-13 | 济南昊雨青田医药技术有限公司 | Treat pharmaceutical composition of alcoholic hepatitis and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102784363A (en) | Traditional Chinese medicine composition for treating pancreatic cancer and preparation method thereof | |
| CN103690784B (en) | The Chinese medicine composition for the treatment of Complicating with Hypentersion nephropathy and preparation method | |
| CN105535263A (en) | Medicine composition for treating ascites due to cirrhosis and preparation method thereof | |
| CN105267906A (en) | Compound chocolate Chinese herbal composition for treating and improving menstrual syndrome of females | |
| CN106668348A (en) | Pharmaceutical composition for treating diabetic retinopathy | |
| CN105535095A (en) | Medicine composition for treating liver ascites | |
| Ligaa et al. | Medicinal plants of Mongolia and their use in traditional medicine | |
| CN105287921A (en) | Medicinal composition for treating gastric cancer and preparation method thereof | |
| CN105617268A (en) | Medicine for treating scale keratinization type beriberi | |
| CN104872331A (en) | Preparation method of mugwort tea | |
| CN104689240A (en) | Medicine for treating Qi-stagnation and blood stasis type chloasma and preparation method thereof | |
| CN109432355A (en) | A kind of Chinese medicine composition of anti-liver cancer and anti-and preparation method thereof | |
| CN115531488B (en) | Composition for soothing liver and strengthening spleen and being used for postoperative adjuvant therapy of breast cancer and preparation method thereof | |
| CN102000303B (en) | Compound traditional Chinese medicine preparation for suppressing tumors | |
| CN109568496B (en) | Detection method of traditional Chinese medicine composition for treating diabetes | |
| CN106109551A (en) | A kind of pharmaceutical composition preventing and treating chloasma | |
| CN106668125A (en) | Pharmaceutical composition for treating optic atrophy and preparation method of pharmaceutical composition | |
| CN105535265A (en) | Pharmaceutical composition for treating pancreatic cancer | |
| CN105535177A (en) | Medicine composition for treating encephalatrophy and preparation method of medicine composition | |
| CN106177396A (en) | A kind of Chinese medicine external compound preparation treating threatened abortion and preparation method | |
| CN106074736A (en) | A kind of pharmaceutical composition treating cerebral thrombosis and preparation method thereof | |
| CN105560694A (en) | Medicine composition for treating diabetic nephropathy and preparation method thereof | |
| CN105288166A (en) | Traditional Chinese medicine composition for thyroid enlargement and preparation method thereof | |
| CN105327009A (en) | Medicinal composition for treating malignant tumor and preparation method thereof | |
| CN104689073A (en) | Medicine for treating yin deficiency and heat-poison type lung cancer and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160504 |